Release Date
Geography
Language of Resource
Full Text Available
Open Access / OK to Reproduce
Peer Reviewed
Objective
This study aims to explore the experiences of patients receiving depot buprenorphine from an Australian publicly operated drug and alcohol service.
Findings/Key points
The majority of participants reported satisfaction with depot buprenorphine across the domains of efficacy, convenience and global satisfaction. Participants perceived benefits as increased convenience, reduced stigmatisation and the inability to ‘skip’ daily Medication Assisted Treatment for Opioid Dependence (MATOD) doses. There were mixed experiences with the ability for depot buprenorphine to ‘hold’ participants throughout the dosing interval. Reduced contact and disconnection from healthcare services were reported as an issue for some participants when initiating depot buprenorphine.
Design/methods
Twenty-eight participants consented to be involved in a mixed methods quantitative verbal survey and qualitative interview process.
